# The Add-On Menu

By Ruth Calder, Enforcement Editor (https://glpwatchdog.org/authors/ruth-calder) | Published: 2026-08-19 | Updated: 2026-10-27

Canonical page: https://glpwatchdog.org/research/the-add-on-menu

> At our August 2026 count, 152 of 560 sellers ran a peptide menu. Ranked by how often items appear, it is almost exactly the inverse of a ranking by evidence, and the reason is commercial rather than clinical.

## Key points

- 152 of 560 sellers run a peptide menu; 127 of those also sell GLP-1s.
- Most offered: NAD (139), sermorelin (109), glutathione (75). None is tested for why it is sold.
- The two with real trial evidence, tesamorelin and PT-141, sit near the bottom.
- Median menu: 3 items. Longest: 20. Menu length is itself a signal.

Just over a quarter of the sellers we track (**152 of 560**) run a peptide menu alongside their GLP-1 offering, and 127 of those also publish GLP-1 prices. Ranked by how often they appear, the menu is almost exactly the *inverse* of a ranking by evidence.

## What is on the menu

*Most frequently offered peptides across 152 seller menus, against the human trial evidence for each.*

| Item | Sellers offering it | Human randomized trials |
| --- | --- | --- |
| NAD | 139 | None of the injected form |
| Sermorelin | 109 | From its history as a growth-hormone agent |
| Glutathione | 75 | Trials exist — in melasma and Parkinson’s, not weight or energy |
| GHK-Cu | 32 | Two |
| PT-141 (bremelanotide) | 29 | Fourteen — an approved drug |
| BPC-157 | 15 | **Zero** |
| Tesamorelin | 11 | Twenty-six — an approved drug |

[Glutathione](https://glpwatchdog.org/peptides/glutathione) deserves a word, because “no evidence” would be wrong. It has a real randomized literature in skin lightening and melasma, in Parkinson’s disease, in autistic children with disruptive behavior and in sepsis. What it does not have is trials for the reasons it appears on these menus. Evidence for one use is not evidence for another, and a seller citing “studies” is not necessarily citing studies of what you are buying it for. The trials are taken one claim at a time in [glutathione: what the evidence shows](https://glpwatchdog.org/research/glutathione-what-the-evidence-shows).

The two items with the most human trial evidence, tesamorelin and [bremelanotide](https://glpwatchdog.org/research/pt-141-bremelanotide-evidence), both became approved drugs, and both sit near the bottom of the menu. The two at the top have the least. We set out the trial counts in [what has human trials and what does not](https://glpwatchdog.org/research/the-peptide-menu-what-has-human-trials).

> Ranked by evidence, the list nearly reverses.

## Why the inversion makes commercial sense

This is not a conspiracy and it does not need one. The items at the top of the menu share properties that have nothing to do with whether they work.

- **They treat something everyone has.** Energy, aging, recovery and general wellness have no diagnostic threshold, so nobody is excluded and nothing can fail.
- **They have no approved indication**, which means no label, no approved claim, and therefore no claim that can be contradicted by one.
- **Nobody can tell whether they worked.** Unlike a GLP-1, where the scale answers within weeks, an energy or longevity product is unfalsifiable at the individual level.
- **They are cheap to add.** The consultation, the prescriber relationship and the shipping already exist, so an extra product is close to pure margin.

The items further down the menu are the opposite: they treat specific conditions, in specific people, with specific measurable outcomes. That makes them harder to sell to everyone, which is exactly why they appear less often.

## The shape of a typical menu

The median menu carries three items; the longest we found carries twenty. A short menu of two or three is usually the top of the list above (NAD, sermorelin, glutathione). Long menus tend to add the research-chemical end, where evidence thins to nothing and, in some cases, lawful compounding stops entirely: see [what cannot legally be compounded](https://glpwatchdog.org/research/what-cannot-legally-be-compounded).

> **Menu length is a signal in itself.** A seller offering twenty peptides is not twenty times more capable than one offering three. It has decided its business is selling injections rather than treating a condition, and that decision shows up in everything else about how it operates.

## What to do at the point of sale

1. **Ask what it is approved for.** For most of the top of that menu, the answer is nothing, anywhere.
2. **Ask how you would know it worked.** If there is no measurable endpoint, you are buying a subscription rather than a treatment.
3. **Ask what it costs annually**, not monthly. Add-ons are priced to look small next to the main product.
4. **Notice when the offer arrives.** Add-ons are usually presented after you have committed to the GLP-1, which is a sales sequence rather than a clinical one.

None of this means the sellers running these menus are bad. Many run them alongside a perfectly reasonable GLP-1 service. It means the menu is a commercial artifact and should be read as one. Its ordering tells you about marketing rather than about medicine.

## Frequently asked questions

### How common are peptide add-ons with GLP-1 sellers?

152 of the 560 sellers we track run a peptide menu, and 127 of those also publish GLP-1 pricing. The median menu carries three items; the longest we found carries twenty.

### Which peptides are offered most?

NAD by a wide margin, at 139 sellers, then sermorelin at 109 and glutathione at 75. Those three are also among the least supported by human trials.

### Why do the best-evidenced peptides appear least?

Because they treat specific conditions in specific people with measurable outcomes, which makes them hard to sell to everyone. The items at the top of the menu target things with no diagnostic threshold (energy, aging, recovery), where nobody is excluded and nothing can be shown to have failed.

### Is a long peptide menu a bad sign?

It is a signal worth reading. A seller offering twenty peptides has decided its business is selling injections rather than treating a condition, and that decision tends to show up elsewhere in how it operates.

### What should I ask before adding one?

What it is approved for, how you would know whether it worked, and what it costs over a year rather than a month. If there is no measurable endpoint, the purchase is a subscription rather than a treatment.

## References

1. GLP Watchdog. Provider register — peptide menu composition recorded from structured product fields across 560 sellers, computed August 19, 2026. GLP Watchdog register. 2026. https://glpwatchdog.org/compare

---

Cite as: GLP Watchdog, Ruth Calder, "The Add-On Menu", published 2026-08-19, updated 2026-10-27. https://glpwatchdog.org/research/the-add-on-menu

Canonical HTML page: https://glpwatchdog.org/research/the-add-on-menu

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.
